Drug intelligence / Profile preview

AST-09X

Development stage: Preclinical
Lead developer: Aston Sci
Modality: Vaccines & Immunotherapeutics

Overview

AST-09X is a therapeutic vaccine in development for the treatment of solid tumors. It is being developed by Aston SCI and is currently in the preclinical stage of research and development. The drug aims to stimulate an immune response against cancer cells, specifically targeting neoplasms with a focus on solid tumor indications[1][4]. The exact mechanism of action has not been fully disclosed, but as a therapeutic vaccine, it likely works by eliciting an immune response against tumor-associated antigens.

Beyond the preview

Go deeper on AST-09X.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AST-09X.

Explore the full profile